作者: Johanna Sofia Margareta Mattsson , Juliana Imgenberg-Kreuz , Karolina Edlund , Johan Botling , Patrick Micke
DOI: 10.1111/J.1365-2559.2012.04245.X
关键词: EGFR inhibitors 、 Epidermal growth factor receptor 、 Lung cancer 、 Microdissection 、 Mutation 、 Oncology 、 KRAS 、 Biology 、 Internal medicine 、 Cancer 、 Mutation testing
摘要: Mattsson J S M, Imgenberg-Kreuz J, Edlund K, Botling & Micke P (2012) Histopathology 61, 744–748 Consistent mutation status within histologically heterogeneous lung cancer lesions Aims: Activating epidermal growth factor receptor (EGFR) and KRAS mutations characterize molecular subgroups of non-small-cell (NSCLC) with a strong predictive value for response to EGFR inhibitor therapy. However, the temporal occurrence clonal stability these during course progression are debated. The aim this study was presence in different areas primary NSCLC lesions. Methods results: Formalin-fixed paraffin-embedded specimens from six cases five were selected pool resected patients. From each tumour, three morphologically distinct manually microdissected analysed mutations. results demonstrated consistent histological all tumours. Conclusions: support concept that activating oncogenic events consistently present throughout tumour independently heterogeneity. Thus, diagnostics, any part is likely be representative testing.